Euro-Zone Business Activity Hits Three-Year High on Services
Private-sector activity in the euro area grew at the fastest pace in more than three years as the service sector unexpectedly improved.
The Composite Purchasing Managers’ Index compiled by S&P Global increased to 53.1 from 52 in August, well above the 50 threshold separating growth from contraction. Analysts in a Bloomberg survey had anticipated a small decline to 51.7.
The region’s two largest economies both exceeded expectations, with activity in Germany growing at the fastest pace since October 2025 and France unexpectedly expanding at the quickest in more than two years.
“Manufacturing, spearheaded by Germany, is enjoying its best growth spell for over four years, spurred by rising AI and defense spending,” Chris Williamson, chief business economist at S&P Global Market Intelligence, said Wednesday in a statement. “But service-sector growth is also perking up to signal a broad-based improvement in the economic growth story.” (…)
Boosts this month to euro-zone manufacturing and services order books hint at “sustained momentum heading into the fourth quarter,” Williamson said. But he noted that economic strength is driving consumer prices higher. (…)
“The resilience of economic growth amid the headwinds of geopolitical issues and rising prices will likely embolden the ECB to hike interest rates again before the end of the year.” (…)
More from S&P Global:
The picture for new orders at eurozone companies was similar to that for business activity, with growth recorded for the third month running in September. Here, the pace of expansion was the strongest since May 2022. Total new orders were supported by a further rise in new export business (which includes intra-eurozone trade).
New export orders increased for the second month running, after having decreased in each of the 53 months prior to August. The overall rise was centred on the manufacturing sector, while services new business from abroad continued to fall.
Meanwhile, staffing levels increased for the second successive month, but only modestly and at the same pace as in August.
Inflationary pressures intensified in September, with both input costs and output prices increasing at the sharpest rates in four months. The latest rise in input costs was faster than the average for the year-to-date, but remained softer than the recent peak seen in May. Accelerated cost inflation was registered across both the manufacturing and services sectors.
Similarly, output prices increased at sharper rates in both monitored sectors, as well as across Germany, France and the rest of the eurozone as a whole.
ING:
A closer look at the data, however, shows that the more dynamic activity stems mainly from services, which jumped significantly from 51.6 to 53.0. What is driving this jump in an environment of higher inflationary pressures remains a bit unclear. Germany, in particular, saw an increase in services activity, from 49.7 to 52.9, which almost looks too good to be true. (…)
All in all, today’s PMI readings are almost too good to be true. A eurozone economy that remains completely unharmed by an energy price shock and supply chain disruptions is a welcome surprise. Let’s hope it doesn’t turn out to be a mirage. At face value, however, today’s PMI readings make it more difficult for even the ECB’s most dovish policymakers to rule out another rate hike.
OECD sounds alarm on surging government bond yields Paris-based forecaster says governments’ debt interest bills are increasing pressure on public finances
(…) The average 10-year benchmark bond yield of G7 countries has hit 4 per cent this year for the first time since 2008. The US war with Iran and ensuing surge in energy prices has fuelled a bond sell-off that reflects investor concerns about rising inflation.
The combination of higher borrowing costs and record bond issuance by governments across the rich world has propelled a rise in debt-servicing costs that is worrying policymakers. (…)
Across the OECD, debt interest costs topped $2tn, or 3 per cent of GDP, last year, and are expected to increase further. In France, the interest bill is expected to rise by a quarter this year, and it already exceeds defence spending in a string of countries. (…)
One route out of the debt squeeze is higher growth. The OECD said AI-related investment and trade is currently helping global growth weather the Gulf oil shock better than expected.
The organisation added that G20 economies will expand by 3.1 per cent this year, 0.1 percentage points more than it forecast in June. The expansion should continue at a similar pace of 3 per cent in 2027, it added.
Rising GDP will be led by stronger than expected growth in the US, where the economy is set to expand by 2.2 per cent this year and 2.1 per cent in 2027, boosted by the data centre construction boom.
The OECD said GDP growth in nations including China, South Korea and Japan is being propelled by technology exports, with the global economy also cushioned by robust oil inventories. (…)
Inflation in G20 countries is set to rise to 4.1 per cent in 2026, up from 3.4 per cent last year, according to OECD forecasts.
It predicts price growth of 3.6 per cent in 2027 — an increase of 0.5 percentage points compared with its prior forecast.
More than half of G20 countries currently have inflation that is above their central banks’ target, the organisation added.
Here’s What’s Happening to the Billions of Dollars of US Tariff Refunds
(…) The February ruling by the high court set in motion steps towards repaying an estimated $166 billion in revenue collected via duties Trump imposed after taking office in January last year.
The bulk of those payments has now been distributed, US Treasury data indicate. After three straight months of net declines in customs duties, flows turned positive again in August. A court filing shows that, as of Sept. 11, about $134.7 billion in refunds, including interest, had been paid out or approved for processing. (…)
A survey released Monday by the Federal Reserve Bank of Atlanta suggested companies are holding on to at least part of the cash. The 220 executives who shared their plans — in a broader survey of more than 1,100 taken last month — ticked multiple boxes in identifying their intentions. (…)
These one-time refunds flow in corporate P&Ls when received, positively impacting margins and profits.
Poll: Americans see rule of law declining in U.S.
A majority of Americans say the rule of law in the U.S. is weaker now than a decade ago, when Donald Trump was first elected president, according to a massive new survey of more than 23,000 U.S. adults.
78% of those responding to the survey by Gallup and the Charles F. Kettering Foundation for its Democracy for All Project say government officials must always follow laws and the Constitution.
But just 28% trust that political leaders will be held accountable if they don’t. (…)
The share of Americans who say the rule of law is weaker now than in 2016 is four times higher than the share who think it’s stronger (56% compared with 14%), while 29% say it’s unchanged. Democrats and independents were much likelier than Republicans to say it’s weaker. (…)
- 49% say they don’t agree with the idea that U.S. leaders are committed to having a strong democracy, up from 44% a year ago.
- 47% say they’re comfortable openly expressing opinions about government and laws, down from 52%.
- 56% say democracy is doing poorly, up from 51% the year before. That sense is largely being driven by rising concerns from Republicans and Republican-leaning independents, while Democrats and neutral independents already were highly critical.
The Trump administration is deploying hundreds of federal investigators and attorneys to pursue President Trump’s long-running fixation — and test a broader Republican claim that tougher enforcement will uncover far more illegal voting.
“This initiative is a tier one priority,” a Justice Department official told reporters on Tuesday. “It’s a top priority for the attorney general and for the White House.” (…)
- DOJ has charged 24 immigrants this calendar year following the prioritization, according to agency press releases. The accused are a mixture of undocumented immigrations and legal residents.
- The number of prosecutions will “rise significantly each week going forward from now until the election,” the DOJ official said.
To support these investigations, which the HSI official called agent-time intensive, Homeland Security staff have shifted work time from other priorities.
HSI agents typically investigate smuggling, trafficking, financial fraud and sexual exploitation crimes.
Roughly 250 million adult U.S. citizens are eligible to vote in the 2026 midterm elections.
The next generation of American scientists is fading away While the Trump administration racks up ‘wins’ in its anti-woke crusade, the US is eroding its talent pipeline
A survey by academics at MIT, Harvard and Australia’s Monash University (…) across US run labs:
Of the junior scientists who responded, a third who once envisaged careers in academia had changed their minds by early 2025, with some PhD students and postdoctoral researchers even rethinking their plans to stay in the country.
The survey was published this summer as a non-peer-reviewed working paper from the National Bureau of Economic Research.
These are not the gripes of career bureaucrats bitter at slashed budgets, the survey’s authors point out, but “the stated intentions of the next generation — the scientists who would, in ordinary times, become the principal investigators of the future”.
These are clearly not ordinary times, and the biomedical research community is now bracing for another potential body blow: according to Politico, an imminent White House executive order will seek to install a political board to vet all National Institutes of Health grants, to weed out “woke” science.
As the Trump administration continues to lob ideological grenades at the nation’s premier centres of scientific research, it is no surprise that some future drug developers, device inventors, life savers and wealth creators are opting to walk away. (…)
More than 900 replied from 134 institutions. While 66 per cent wanted to stay in academia six months before the survey, that fell to 44 per cent by March 2025. When it came to remaining in the US, just 72 per cent were keen, a drop from 93 per cent six months earlier.
The authors acknowledge there may be “recall bias”, and that intentions change, but describe young researchers as “the canary in the coal mine” for US scientific research. (…)
- Biotech is one area where the US can afford to let China flourish Drugmakers are picking through the Chinese biotech sector to find treatments and technologies to bring to overseas markets
(…) Drugmakers from around the world are picking through China’s biotech sector to find treatments and technologies they can bring to overseas markets. So far this year, companies have signed licensing deals worth $110bn, if all milestones are met, according to biopharma data gatherer Sleuth. That is roughly a $20bn increase on last year. (…)
There’s an obvious commercial logic to this. Medicines may be hatched in Chinese labs but the illnesses they treat, including cancer and autoimmune diseases, are global. (…)
Trump tends to take a hawkish view of capital flowing away from the US. He signed the Biosecurity Act into law at the end of last year, aiming to curb dealmaking with China’s biotech sector. Three similar pieces of legislation are wending their way through the system. WuXi AppTec was blacklisted for alleged military ties — a decision subsequently blocked by a US federal judge.
But trying to squash Chinese biotech is both impractical and unwise. For one, the industry is fairly self-sufficient; unlike tech, say, Washington cannot opt to withhold component parts such as chips. China has the entire chain sewn up, from brainpower and raw materials to speedy clinical trials — trial recruitment is up to five times quicker than in the West, says McKinsey — and manufacturing.
Capital, too, is in ample supply. Chinese companies can tap local and, via Hong Kong, international markets. There is likely to be state support too. Beijing, which last week released its five-year plan for the pharma industry, wants China to develop at least a quarter of the world’s first-in-class drugs.
One reason even trade-sceptical Americans should welcome the biotech trend is that they don’t have easy options if the flow of drugs is impeded. Cars, smartphones and Labubu dolls — or reasonable substitute products — can all be sourced at home. It is an altogether different proposition to withhold access to world-class treatments.
AI remains an area of enormous tension between superpowers because in the race to superintelligence, it may be that there can only be one winner. In drugmaking, though, there can be many. If Chinese labs are coming up with innovative treatments and technologies, the rest of the world should cheer them on — and leave their protectionist tendencies for other sectors.
Indeed. But there goes the US bargaining (bullying) power. If you think rare earths are big bargaining chips, how about effective cancer treatments?
FYI
@Barchart

